Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab Ravtansine QTc Study
NCT05429762Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Oct 2022
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of tusamitamab ravtansine in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), gastric cancer (GC) and 1 more, sponsored by Sanofi. Primary endpoint: Change from baseline in QT-interval corrected (QTcF) centrally assessed at Cycle 2. Started Oct 2022; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05429762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429762.